Streetbeat News

Regulatory

DLTR

FIVE

Donald Trump's plan to impose tariffs could lead to increased prices for goods and services, potentially affecting the stock prices of retailers like Five Below and Dollar Tree.

Portfolio Pulse from

November 07, 2024 | 8:00 pm

FSLR

Despite initial concerns following Donald Trump's presidential victory, UBS believes the growth of the renewable energy sector is likely to continue. However, the potential repeal of the previous administration's Inflation Reduction Act (IRA) poses a risk.

Portfolio Pulse from

November 07, 2024 | 7:45 pm

META

TSM

AI stocks, including Taiwan Semiconductor and Meta Platforms, rallied due to looser regulatory restrictions and increased focus on AI from the incoming presidential administration.

Portfolio Pulse from

November 07, 2024 | 7:00 pm

FNMA

Fannie Mae has approved the MPF Program to facilitate lending to Native Americans on tribal trust lands, enhancing access to conventional loans through the NACLI program.

Portfolio Pulse from

November 07, 2024 | 6:30 pm

XHB

The re-election of Donald Trump in the 2024 Presidential Election led to a short-term boost in major stock market indices. However, the SPDR S&P Homebuilders ETF (XHB) declined due to concerns over tariffs and economic policies affecting housing affordability.

Portfolio Pulse from

November 07, 2024 | 6:30 pm

GERN

Geron Corporation's imetelstat, branded as Rytelo, received FDA approval in June for treating lower risk myelodysplastic syndromes and is showing strong initial sales. The company reported Q3 results and announced new financing. Analysts are optimistic about Geron's future.

Portfolio Pulse from

November 07, 2024 | 6:15 pm

NVO

Novo Nordisk A/S announced trading activities in its shares by board members, executives, and associated persons, as per market abuse regulations.

Portfolio Pulse from

November 07, 2024 | 5:45 pm

THCX

Cannabis stocks experienced a significant decline after Amendment 3, which aimed to legalize recreational marijuana use in Florida, failed to pass. The amendment did not achieve the required 60% support, impacting the cannabis market negatively.

Portfolio Pulse from

November 07, 2024 | 5:30 pm

AZN

AstraZeneca's stock has dropped due to a fraud investigation in China, but the company's strong H1 2024 performance and positive outlook for Q3 2024 make it an attractive buy. The recent price drop has also improved its forward P/E ratio.

Portfolio Pulse from

November 07, 2024 | 5:30 pm